Finoriq research workspace
BIOCRYST PHARMACEUTICALS INC (BCRX) Institutional Holdings & 13F Ownership
BIOCRYST PHARMACEUTICALS INC markets peramivir injection, an intravenous neuraminidase. Review BCRX institutional holders, 13F ownership, and position changes on Finoriq.
Company Snapshot
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
- Company
- BIOCRYST PHARMACEUTICALS INC (BCRX)
- Ticker
- BCRX
- Market Cap
- $2.3B
- Latest Price
- $9.205
- Industry
- Biotech & Pharma
BIOCRYST PHARMACEUTICALS INC (BCRX) Top Institutional Holders
Top current 13F holders indexed for BIOCRYST PHARMACEUTICALS INC (BCRX). Latest period 2026-03-31.
| Rank | Investor | Value | Portfolio | Filing |
|---|---|---|---|---|
| 1 | Ken FisherCIK 0000850529 | $26M | 0.01% | Filing2026-05-05 |
| 2 | Ray DalioCIK 0001350694 | $6.1M | 0.03% | Filing2026-05-15 |
| 3 | Joel GreenblattCIK 0001510387 | $3M | 0.01% | Filing2026-05-15 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.